// App-Quantinova.ai

4379 : Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

Researchers

Presenter

  • Mandy Lawson

Principal Investigators

  • Natalie Cureton

  • Michelle DuPont

  • Oona Delpuech

  • Dawn Trueman

  • Pei Zhang

  • Azadeh Cheraghchi-Bashi-Astaneh

  • Sladjana Gagrica

  • Gareth Maglennon

  • Daniel Sutton

  • Bairu Zhang

  • Jonathan Cairns

  • Jamie Scott

  • Teresa Klinowska

  • Christopher J. Morrow

Medical Centers

  • AstraZeneca, United Kingdom.

  • Astra-Zeneca, MD.

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Progesterone receptor

  • Proliferation marker protein Ki-67

  • Estrogen Receptor 1

Drug/Treatment

  • Fulvestrant

  • Alora

  • Tamoxifen

  • AZD-9496

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved